-
Internal medicine journal · Apr 2012
When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?
- R J Bird, M Kenealy, C Forsyth, J Wellwood, M F Leahy, J F Seymour, and L B To.
- Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. robert_bird@health.qld.gov.au
- Intern Med J. 2012 Apr 1; 42 (4): 450455450-5.
AbstractDespite the absence of a robust evidence base, there is growing consensus that effective treatment of iron overload leads to decreased morbidity and premature mortality in patients with good prognosis myelodysplastic syndromes (MDSs). Furthermore, new treatment modalities, including disease-modifying therapies (lenalidamide and azacytidine) and reduced intensity conditioning therapies for allogeneic blood stem cell transplants, are offering the prospect of longer survival for patients with traditionally less favourable prognosis MDS, who might also benefit from iron chelation. This article proposes assessment of patients with MDS and related bone marrow failure syndromes to determine suitability for iron chelation. Iron chelation therapy options and monitoring are discussed.© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..